je.st
news
Tag: alexion
Alexion: 2 Global Drug Rollouts, But Upside Already Priced In
2015-12-06 11:18:40| Biotech - Topix.net
Alexion is highly overvalued, even assuming best case peak sales projections of $1B for Strensiq, $1B for Kanuma, and $5B for Soliris. Payer risk for high-priced drugs isn't going away and orphan drug companies can't expect to keep getting a free pass.
Alexion Receives Notification of PDUFA Date Extension for Kanuma ...
2015-09-04 23:15:02| Biotech - Topix.net
Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act date for its Priority Review of the Company's Biologics License Application for Kanuma a , an investigational enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency . The previously disclosed September 8, 2015 PDUFA date has been extended by the standard extension period of three months.
Tags: date
extension
notification
receives
Alexion gets EU approval for drug acquired in Synageva deal
2015-09-02 03:25:24| Biotech - Topix.net
Ten weeks after closing its $8.4 billion purchase of Synageva BioPharma Corp, Alexion Pharmaceuticals Inc on Tuesday announced European approval for the key drug acquired through the deal, an enzyme-replacement therapy for an ultra-rare, life threatening disease. European health regulators approved Kanuma for patients with lysosomal acid lipase deficiency .
Alexion Completes Acquisition of Synageva
2015-06-23 15:40:56| Biotech - Topix.net
CHESHIRE, Conn.-- -- Alexion Pharmaceuticals, Inc. announced today that it has successfully completed its previously announced acquisition of Synageva BioPharma Corp. , strengthening its global leadership in devastating and rare diseases, and creating the most robust rare disease pipeline in the biotech industry across a range of therapeutic modalities. The transaction was completed through a merger of Synageva with and into a direct, wholly owned subsidiary of Alexion.
Tags: acquisition
completes
completes acquisition
alexion
Alexion buys Lexington rare drug maker Synageva for $8.4B
2015-06-23 15:40:55| Biotech - Topix.net
With the completion of the $8.4 billion acquisition of Synageva BioPharma by a Connecticut pharmaceutical company specializing in marketing extremely rare drugs, the Bay State has one fewer locally-owned, publicly-traded biotech firm. In a statement today, Alexion , which reported 2,273 employees as of the end of last year, said its combination with 282-employee Synageva gives it a new total head count of "more than 2,800 employees."